Company Overview

Skymab Biotherapeutics is a CEA* spin-off biotech company committed to the design, engineering and development of antibodies targeting G Protein Coupled Receptors (GPCR) with a main focus in oncology.

Skymab was founded by enthusiastic scientists and entrepreneurs, thrilled to combine the most valuable technical knowledge in antibody discovery with their challenging know how in GPCR to create innovative tailored antibodies that achieved specific therapeutic strategies.

* French Atomic Agency (CEA), the most innovative public research organization in Europe according to a REUTERS ranking.

Our mission

Using our discovery and development antibodies platform, we are aiming at identifying GPCRs targets with the most relevant potential to pioneer a new range of first and best in class antibodies intended to diagnostic and therapeutic applications for diseases with significant medical needs.